Abstract
Since 2021, the number of targeted drugs available for the treatment of relapsed or refractory lymphoma has been shrinking rather than growing. This falling number of treatment options comes with the announcement of withdrawals of several PI3K inhibitors in development for indolent B-cell lymphomas, including follicular lymphoma, because of an increased proportion of deaths in patients receiving PI3K inhibitors. Additionally, the histone deacetylase inhibitor, romidepsin, has been restricted to cutaneous T-cell lymphoma, because of the negative results of the Ro-CHOP study in patients with peripheral t-cell lymphoma.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
